Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits
Authors:
- Martin KallabMKMartin Kallab
- Kornelia SchuetzenbergerKSKornelia Schuetzenberger
- Nikolaus HommerNHNikolaus Hommer
- Bhavapriya Jasmin SchäferBSBhavapriya Jasmin Schäfer
- Doreen SchmidlDSDoreen Schmidl
- Helga BergmeisterHBHelga Bergmeister
- Markus ZeitlingerMarkus Zeitlinger
- Aimin TanATAimin Tan
- Phatsawee JansookPJPhatsawee Jansook
- Thorsteinn LoftssonTLThorsteinn Loftsson
- Einar StefanssonESEinar Stefansson
- Gerhard GarhöferGGGerhard Garhöfer
Open Access
- 18 May 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (5) , 480
Abstract
The purpose of this study was to evaluate the ocular pharmacokinetics, bio-distribution and local tolerability of γ-cyclodextrin (γCD) based irbesartan 1.5% eye drops and candesartan 0.15% eye drops after single and multiple topical administration in rabbit eyes. In this randomized, controlled study, a total number of 59 New Zealand White albino rabbits were consecutively assigned to two study groups. Group 1 (n = 31) received irbesartan 1.5% and group 2 (n = 28) candesartan 0.15% eye drops. In both groups, single dose and multiple administration pharmacokinetic studies were performed. Rabbits were euthanized at five predefined time points after single-dose administration, whereas multiple-dose animals were dosed for 5 days twice-daily and then euthanized 1 h after the last dose administration. Drug concentration was measured by using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in the retinal tissue, vitreous humor, aqueous humor, corneal tissue and in venous blood samples. Pharmacokinetic parameters including maximal drug concentration (Cmax), time of maximal drug concentration (Tmax), half-life and AUC were calculated. To assess local tolerability, six additional rabbits received 1.5% irbesartan eye drops twice daily in one eye for 28 days. Tolerability was assessed using a modified Draize test and corneal sensibility by Cochet Bonnet esthesiometry. Both γCD based eye drops were rapidly absorbed and distributed in the anterior and posterior ocular tissues. Within 0.5 h after single administration, the Cmax of irbesartan and candesartan in retinal tissue was 251 ± 142 ng/g and 63 ± 39 ng/g, respectively. In the vitreous humor, a Cmax of 14 ± 16 ng/g for irbesartan was reached 0.5 h after instillation while Cmax was below 2 ng/g for candesartan. For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and max 5.64 ± 4.08 ng/mL) and candesartan (Cmax 4.32 ± 1.04 ng/mL) were reached 0.5 h (Tmax) after single administration. Local tolerability was favorable with no remarkable differences between the treated and the control eyes. These results indicate that irbesartan and candesartan in γCD based nanoparticle eye drops can be delivered to the retinal tissue of the rabbit’s eye in pharmacologically relevant concentrations. Moreover, safety and tolerability profiles appear to be favorable in the rabbit animal model.Keywords
Funding Information
- Eurostars (PREVIN E11008)
This publication has 40 references indexed in Scilit:
- Cyclodextrin-Mediated Enhancement of Riboflavin Solubility and Corneal PermeabilityMolecular Pharmaceutics, 2013
- Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical reviewInternational Journal Of Clinical Practice, 2011
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesNew England Journal of Medicine, 2009
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialThe Lancet, 2008
- Effect of systemic administration of valsartan, an angiotensin II type 1 receptor blocker, on retinal circulation in healthy humansEye, 2008
- Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eyeActa Ophthalmologica Scandinavica, 2007
- Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye dropsJournal of Pharmacy and Pharmacology, 2007
- Phase solubility and structure of the inclusion complexes of prednisolone and 6α‐methyl prednisolone with various cyclodextrinsJournal of Pharmaceutical Sciences, 2005
- Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administrationJournal of Controlled Release, 2005
- Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constrictionJournal of the Renin-Angiotensin-Aldosterone System, 2001